Category Archives: Performance

MEMOTEXT® and Metabolic Markets, LLC announce strategic partnership


MEMOTEXT and Metabolic Markets have entered into a strategic partnership, integrating MEMOTEXT’s best-in-class patient adherence platform into the Metabolic Markets’ client offerings.

“Patient compliance and adherence has long been one of the biggest challenges in chronic disease management.  MEMOTEXT’s unique, customized programs aimed at individualizing and increasing patient engagement, result in improved compliance and provide significant value to the healthcare system by reducing the overall impact and increased positive patient outcomes” stated Metabolic Markets partner Dr. Damon Tanton.

MEMOTEXT CEO Amos Adler commented, “Integrating Metabolic Markets clinical and health system expertise further enhances the delivery of MEMOTEXT’S adherence solution to patients, health care providers and payers.  We look forward to expanding the utilization of MEMOTEXT’s platform throughout the health care continuum with the Metabolic Markets partnership.”

Metabolic Markets will promote { MEMOTEXT’s patient compliance platform across its client base of manufacturers, managed care organizations and government health systems.


MEMOTEXT® integrates behavior modification, patient education and real-time patient support into the everyday lives of patients. This approach improves adherence using interactive multimedia assessment and telecommunications tools.

About Metabolic Markets

Metabolic Markets is the first strategic sale/marketing/reimbursement consulting company to focus on the unique commercial challenges in diabetes, obesity and other metabolic disorders.

Metabolic Markets was founded by Aaron Davis and Dr. Damon Tanton under the belief that bringing commercial and clinical expertise together in a focused consultancy will deliver enhanced value to clients, improving access and increasing treatment modalities in the global healthcare crisis of diabetes and obesity.


Bydureon: if you build it, will they come? We will know soon

Amylin and Alkermes announced last week that Bydureon was now available in U.S pharmacies.  

(On a side note, I love any launch press release with “first and only” in the headline.  I’m sure that was mentioned in every market research session as “important,” it happens every new launch, I love looking for it, but I digress.)

What I do like about the press release announcing Bydureon’s availability is the comprehensive approach Amylin is taking.  They are leaving nothing to chance:

A) Live patient support, and apparently an “in-person” education session if needed

B) A co-pay coupon card for up to 24 months at $50/month value

It does appear that Amylin has learned from past issues, and is providing what is needed to support the product, considerably different than Byetta’s launch.

This is the first picture I have seen of the Bydureon presentation, it does not look particularly easy, but with the patient support offered, the kit itself should not be too tall a barrier.

The billion dollar question will be, does once weekly injection change physician prescribing habits, even if patients can learn to manage the Bydureon kit?

Time will soon tell.

email me you predictions for Bydureon.  closest to the pin for U.S. market share at the end of the year wins a Metabolic Markets t-shirt.

Bydureon vs. Victoza? Super Bowl? M2 makes our prediction

Metabolic Markets has developed a GLP-1 market briefing for our clients education and discussion. Entitled: “The U.S. GLP-1 Market Brief: Yesterday, Today, and Tomorrow”  The brief slide deck reviews the history of Byetta, shares our clinical and commercial experience, Victoza introduction, and short term considerations to watch as the market unfolds with the pending Bydureon launch.

Available to you, dear reader,  for only the cost of an email:  

The Franchise – Januvia / the 800 lb gorilla

Merck release 2011 results yesterday, and to no surprise, the Januvia machine, 800 lbs gorilla, or as I like to call it “The Franchise,” continues to perform.

The Franchise posted $3.324 billion in 2011 global sales, up from $2.38 billion in 2010.  Let’s contrast this to the later entrants in the DPP-IV class

Galvus: $677 million (all ex-US, not bad), Onglyza; $156 million, and Tradjenta (only launched mid-2011, BI/Lilly have not reported product level sales for Trajenta)

Januvia, approved in 2006, has been a tremendous success. I remember the pre-launch “expert” chatter about the DPP-IV class: “modest efficacy, no one will use it”, the “ubiquity of the DPP-IV enzyme, so who knows what else is suppressed-safety issues are sure to be uncovered.”  In short, the  market  has not cared one bit about these early concerns.  The modest efficacy matched with tolerability and a clean safety profile (so-far), was just what primary care needed at the time.  One must remember the emerging concerns around the TZD class at the time.  Januvia was also the beneficiary of Galvus’ FDA problems in 2007, and Novartis never re-submitted in the U.S.

So Januvia was born under a lucky star, but it also is a clean, reasonably effective agent.  It now serves as Merck’s platform for diabetes care and co-morbid conditions.  Could Januvia be a $5 billion dollar franchise within two years while the other DPP-IVs scuffle along?